News Releases

 
News Releases
  Date Title and Summary View
Nov 7, 2016
-- Oral presentation at the American Society of Nephrology (ASN) Kidney Week 2016 to highlight Phase II AAV CLEAR trial results -- -- Oral presentation at the American College of Rheumatology (ACR) 2016 Annual Meeting to highlight Phase II AAV CLASSIC trial results -- MOUNTAIN VIEW, Calif., Nov. 07, 2016 (GLOBE NEWSWIRE) -- ChemoCentryx, In...
Oct 28, 2016
MOUNTAIN VIEW, Calif., Oct. 28, 2016 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq:CCXI), today announced that the Company's third quarter 2016 financial results will be released after market close on Monday, November 7, 2016. ChemoCentryx executive management will host a conference call beginning at 5:00 p.m. Eastern Time on November 7, 2016, ...
Oct 27, 2016
MOUNTAIN VIEW, Calif., Oct. 27, 2016 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq:CCXI), today announced that its orally administered complement 5a receptor inhibitor CCX168 (newly designated "avacopan") has shown a beneficial effect on disease in a patient with C3 glomerulopathy (C3G). C3G is a rare disease of the kidney characterized by depo...
Oct 20, 2016
MOUNTAIN VIEW, Calif., Oct. 20, 2016 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq:CCXI), today announced that effective October 17, 2016, Henry A. McKinnell, Jr, Ph.D., retired chairman and chief executive officer of Pfizer Inc., has been appointed to the Company's Board of Directors. Dr. McKinnell brings significant leadership in operations, ...
Oct 18, 2016
-- CCX872 reduced hepatic inflammation, steatosis, and scarring in models of non-alcoholic steatohepatitis (NASH) -- -- Findings reported at the American College of Gastroenterology (ACG) 2016 Annual Meeting -- MOUNTAIN VIEW, Calif., Oct. 18, 2016 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq:CCXI) today announced the presentation of da...
Oct 17, 2016
MOUNTAIN VIEW, Calif., Oct. 17, 2016 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq:CCXI), today announced that positive data from an ongoing Phase II proof-of-concept study of CCX168 for the treatment of Atypical Hemolytic Uremic Syndrome (aHUS) will be presented at the American Society of Nephrology (ASN) Kidney Week 2016 Annual Meeting. CCX16...
Sep 1, 2016
MOUNTAIN VIEW, Calif., Sept. 01, 2016 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq:CCXI) today announced initial 12 week overall response rate (ORR) results from an ongoing open label, single arm Phase Ib clinical trial with CCX872 in patients with advanced pancreatic cancer. CCX872 is a selective inhibitor of the chemokine receptor known as C...
Aug 25, 2016
MOUNTAIN VIEW, Calif., Aug. 25, 2016 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq:CCXI), a clinical-stage biopharmaceutical company developing orally-administered therapeutics to treat autoimmune diseases, inflammatory disorders, and cancer, today announced that Thomas J. Schall, Ph.D., President and Chief Executive Officer, will present at th...
Aug 8, 2016
-- Successfully Completed Phase II ANCA-Associated Vasculitis (AAV) Development Program of Complement 5a Receptor Inhibitor CCX168 -- -- Awarded EMA PRIority MEdicines (PRIME) Designation for Accelerated Assessment of CCX168 in AAV, as well as FDA Orphan Products Development Grant for CCX168 for Treatment of AAV -- -- Plan to Report Initial D...
Aug 1, 2016
MOUNTAIN VIEW, Calif., Aug. 01, 2016 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq:CCXI), a clinical-stage biopharmaceutical company developing orally-administered therapeutics to treat autoimmune diseases, inflammatory disorders and cancer, today announced that the Company's second quarter 2016 financial results will be released after market c...
Page: FirstPrevious
2
... NextLast
= add release to Briefcase